Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Bimekizumab Biosimilar - Anti-IL17A, IL17F mAb - Research Grade |
---|---|
Source | CAS 1418205-77-2 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Bimekizumab,CDP4940,IL17A, IL17F,anti-IL17A, IL17F |
Reference | PX-TA1342 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Bimekizumab has beeninvestigated for the treatment of Psoriatic arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, and Mild to Moderate Psoriasis.
Immobilized IL17A, C-His, recombinant protein (cat. No.PX-P5780) at 0.5µg/mL (100µL/well) can bind to Bimekizumab Biosimilar - Anti-IL17A, IL17F mAb (cat. No.PX-TA1342) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Related products
Reviews
Il n’y a pas encore d’avis.